Immunterapi mod Alzheimers sygdom
Sammanfattning
Passive anti-beta-amyloid (Aß) immunotherapy has been shown to clear brain Aß deposits. Results from phase III clinical trials in mild-to-moderate Alzheimer’s disease (AD) patients with two monoclonal antibodies bapineuzumab and solanezumab
and intravenous immunoglobulin have been disappointing. Subsequent analysis of pooled data from both phase 3 trials with solanezumab showed a reduction in cognitive decline in patients with mild AD. Solanezumab and new monoclonal antibodies are
being tested in patients with prodromal and preclinical AD in search for a disease-modifying treatment.